[The screening of congenital adrenal hyperplasia. Applicability in Galicia]

Rey-Liste T, Garcia-Caeiro A
Record ID 32005000346
Authors' objectives:

The main objective of this report is to provide information about the efficacy/effectiveness of the neonatal screening for congenital adrenal hyperplasia in order to make a decision about adding this condition to the preexistent routine neonatal screening.

Authors' results and conclusions: 17 original articles and two systematic reviews were included. The analysed studies show that the neonatal screening of congenital adrenal hyperplasia advances the date of diagnosis of the illness and detects most children at risk of presenting a salt-wasting crises before these appear. The sensibility of the screening oscillates between 83% and 97%, the specificity is close to 100% and the positive predictive value is very variable, being always below 50%.
Authors' recommendations: Neonatal screening for congenital adrenal hyperplasia advances the moment of the diagnosis of the illness and in consequence the beginning of the treatment, this prevents the appearance of salt-wasting crisis that could lead to the newborn death. Discrepancies exist as to which is the most appropriate protocol for the development of the screening program. The most critical aspects are: the threshold of 17-hydroxyprogesterone that should be considered as an abnormal result and the moment of sample taking. For the introduction of this screening program it is necessary to consider, not only the results of the scientific knowledge, but also the circumstances and real consequences in a certain population.
Authors' methods: Systematic review
Project Status: Completed
Year Published: 2004
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Spain
MeSH Terms
  • Adrenal Hyperplasia, Congenital
  • Costs and Cost Analysis
  • Mass Screening
  • Neonatal Screening
Organisation Name: Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
Contact Address: Conselleria de Sanidade, Xunta de Galicia, San Lazaro s/n 15781 Santiago de Compostela, Spain. Tel: 34 981 541831; Fax: 34 981 542854;
Contact Name: avalia-t@sergas.es
Contact Email: avalia-t@sergas.es
Copyright: Galician Agency for Health Technology Assessment (AVALIA-T)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.